Articles

Medical management services provider, Europital, has announced the opening of a new site in Oxford, United Kingdom, in response to demand from small and medium innovators within the biotech industry.

Europital Opens Oxford Site to Expand Services to UK Biotech

Mapp has selected Avid to provide process transfer, scale-up, and clinical manufacturing services for one of its development programs for a novel antiviral drug candidate.

Avid to Develop Mapp Biopharmaceutical’s Antiviral Drug Candidate in Clinical

Merck’s anti-PD-1 therapy, Keytruda, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency.

Keytruda Receives Two New Approvals in Japan

AstraZeneca has dosed the first participants in its Phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of a combination of two monoclonal antibodies (mAbs) for the prevention and treatment of COVID-19.

AstraZeneca Initiates Phase I Trial of Monoclonal Antibody Combination for COVID-19

The European Commission (EC) and Moderna have concluded exploratory talks on the potential purchase of Moderna’s COVID-19 vaccine candidate for Europeans.

EC and Moderna Conclude Exploratory Talks on Vaccine Supply for Europe

Müller + Müller will become part of DWK upon closing in September 2020 and will continue to function under the same name and management. 

DWK Life Sciences to Acquire Müller + Müller

FDA issued an emergency use authorization for COVID-19 convalescent plasma treatments following a report on NIH concerns about insufficient studies and data. 

FDA Issues EUA for COVID-19 Convalescent Plasma 

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.


Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

The Phase II trial is a randomized, placebo-controlled, observer-blinded study that will include patients aged 18 to 84 years.

Novavax’s COVID-19 Vaccine Candidate Enters into Phase II Clinical Trials

Jill Wechsler is BioPharm International's Washington Editor, jillwechsler7@gmail.com.

FDA announced it had issued an emergency use authorization for convalescent plasma that would make it easier to provide this treatment to COVID-19 patients. 

News